CYTOMEL
Generic: LIOTHYRONINE SODIUM
Pfizer Laboratories Div Pfizer IncManufacturer
ORALRoute
LIOTHYRONINE SODIUMActive Substance
1956-05-08Original Approval
CYTOMEL is FDA application NDA010379, sponsored by KING PHARMS. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2023-12-04
Liothyronine Sodium Tablets, USP 5 mcg, 100-count bottle, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc. CFailed Impurities/Degradation Specifications
Class II2014-04-22
Liothyronine Sodium Tablets, USP 5 mcg, Rx Only, a) 100-count bottle NDC 42794-018-02 and b) 1000-count bottle NDC 42794Cross Contamination with Other Products: Four lots of Liothyronine Sodium Tablets, USP 5 mcg are bei
Class II2023-10-20
Liothyronine Sodium Tablets, USP, 5 mcg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc.Failed Impurities/Degradation Specifications.
Class II2023-10-20
Liothyronine Sodium Tablets, USP, 25 mcg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, IncFailed Impurities/Degradation Specifications.
Top Reported Reactions
1
HEADACHE
500 reports
2
DRUG INEFFECTIVE
460 reports
3
HYPERTENSION
358 reports
4
DYSPNOEA
328 reports
5
HYPOTHYROIDISM
321 reports
6
ASTHMA
309 reports
7
FATIGUE
305 reports
8
THERAPEUTIC PRODUCT EFFECT INCOMPLETE
298 reports
9
GASTROOESOPHAGEAL REFLUX DISEASE
293 reports
10
BURNING SENSATION
286 reports